Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

BURLINGTON, Mass. - Azenta, Inc. (NASDAQ: AZTA), a global provider of life sciences solutions, announced the election of ...

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...

A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...